BlinkLab Reports Early Positive Results From Genetic Autism Study
BB1: $0.590 +3.51% · MC: $106M
BlinkLab reported statistically significant differences in smartphone-based sensory and movement tests between people with a SHANK2 mutation and comparison groups in an exploratory study. The mutation group was small, with fewer than ten participants completing the assessment. Results arrived ahead of the previously expected early next year, while the study does not change the company’s FDA pivotal program for its autism test. BlinkLab expects further exploratory study results before the end of this year.

Comments